Robert Hershberg - 17 Sep 2025 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Reporting relationship: President and CEO, Director
Issuer ticker: HLVX
Reported as of: 17 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Sep 2025, 16:30:17 UTC
Prior SEC filing: 23 Jun 2025
Next SEC filing: 06 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Paul Bavier, Attorney-in-Fact for Robert Hershberg

Key filing fact

Robert Hershberg filed Form 4 for HilleVax, Inc. (HLVX) on 17 Sep 2025.

Key facts

This page summarizes Robert Hershberg's Form 4 filing for HilleVax, Inc. (HLVX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Sep 2025, 16:30.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001274139 Primary reporting owner

HERSHBERG ROBERT

Relationship: President and CEO, Director
Address: C/O HILLEVAX, INC., 321 HARRISON AVE, SUITE 500, BOSTON
Signature: /s/ Paul Bavier, Attorney-in-Fact for Robert Hershberg
Signature date: 17 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HLVX transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -1,101,498
Change %: -100%
Price
Shares after: 0
Date: 17 Sep 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Robert Hershberg is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.